title: Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction.
authors.affiliation: Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC. Electronic address: jcicci@unch.unc.edu.
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Cicci
authors.affiliation: Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC.
authors.forename: Larry
authors.initials: L
authors.lastname: Buie
authors.affiliation: Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC.
authors.forename: Jill
authors.initials: J
authors.lastname: Bates
authors.affiliation: Division of Hematology Oncology, University of North Carolina School of Medicine, Chapel Hill, NC.
authors.forename: Hank
authors.initials: H
authors.lastname: van Deventer
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000069448:Denosumab; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology*; D007674:Kidney Diseases / Q000150:complications* / Q000503:physiopathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications*; D053245:RANK Ligand / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D053245:RANK Ligand; D000069448:Denosumab
keywords: Denosumab; Hypercalcemia; Multiple myeloma; RANK ligand inhibitor; Renal dysfunction